Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment

Key Inclusion Criteria:

1. Must have a documented eligible invasive and/or severe fungal disease that isrefractory or intolerant to Standard-of-Care treatment

2. Be able to tolerate medication orally or through a nasogastric (NG) tube orpercutaneous endoscopic gastrostomy (PEG) tube

3. Be able to understand and sign a written informed consent form (ICF), which must beobtained prior to treatment and any study-related procedures.

4. Be able to understand and sign a consent or authorization form which shall permitthe use, disclosure and transfer of the subject's personal health information. (e.g., in the U.S. HIPAA Authorization form).

5. Be able to understand and follow all study-related procedures including study drugadministration.

6. Agree to use a medically acceptable method of contraception while receivingprotocol-assigned product.

Key Exclusion Criteria:

1. An invasive fungal disease with CNS involvement.

2. Subject has an inappropriately controlled fungal disease source (e.g., persistentcatheters that cannot be removed and are likely the source of infection).

3. Subject is hemodynamically unstable, requiring vasopressor medication for bloodpressure support.

4. A life expectancy < 30 days.

5. Subject with abnormal liver test parameters: aspartate aminotransferase (AST),alanine aminotransferase (ALT) >10 x the upper limit of normal (ULN), and/or totalbilirubin > 5 x ULN.

6. Subject is pregnant or lactating.

7. Subject has used an investigational drug within 30 days prior to the baseline visit.